A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

PHASE3CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

July 6, 2020

Primary Completion Date

February 7, 2022

Study Completion Date

May 20, 2024

Conditions
HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions
DRUG

Mavacamten

Mavacamten Capsules Other names: MYK-461

DRUG

Placebo

Placebo

Trial Locations (21)

10016

Local Institution - 0010, New York

10595

Local Institution - 0017, Valhalla

15212

Local Institution - 0019, Pittsburgh

19104

Local Institution - 0003, Philadelphia

27710

Local Institution - 0004, Durham

33331

Local Institution - 0021, Weston

37205

Local Institution - 0014, Nashville

37235

Local Institution - 0018, Nashville

44195

Local Institution - 0020, Cleveland

48109

Local Institution - 0006, Ann Arbor

49503

Local Institution - 0013, Grand Rapids

55905

Local Institution - 0015, Rochester

63110

Local Institution - 0005, St Louis

77030

Local Institution, Houston

90027

Local Institution - 0009, Los Angeles

97239

Local Institution - 0002, Portland

94305 5406

Local Institution - 0011, Stanford

06520

Local Institution - 0001, New Haven

02114-2696

Local Institution - 0016, Boston

02115

Local Institution - 0007, Boston

84107-5701

Local Institution - 0012, Murray

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY